Concept Life Sciences extends GLP accreditation to support regulatory studies
![](/46/pdcnewsitem/07/53/81/clip_image002.jpg)
Accreditation ensures quality and integrity of non-clinical laboratory studies to support pharmaceutical and biotech industries.
Concept Life Sciences has announced the expansion of its regulatory GLP (good laboratory practice) capabilities at the Group’s Dundee and Bradford sites. The MHRA has confirmed the extension of Dundee’s in vitro capabilities to cover a range of additional assays, and Bradford can now offer a range of integrated GLP regulatory studies to further support pharmaceuticals, medical devices and healthcare.
The breadth of services offered to customers at all stages of discovery and development now also covers compounds going through pre- and post-clinical regulation studies, eventually up to IND. In addition to its original non-regulatory services, the company’s regulatory offering now includes a wide range of assays for enzyme activity, microsomal inhibition, metabolite identification, and cell culture, including hepatocyte induction studies.
The extension forms part of a phased plan to expand GXP compliance (including GLP and GMP) at Concept’s facilities across the UK. Concept’s GXP compliance plan will increase the services it offers for the manufacture of API material, and enable the Group to further support the development of compounds from the discovery stage to full IND packages, providing increased assurance of data integrity and compliance with international standards to ensure acceptance of data by global regulatory bodies.
John Handley, Chief Operating Officer, Concept Life Sciences, said: “The extension of our GLP accreditation by the MHRA in both Dundee and Bradford enables us to further expand the growing portfolio of services we offer to our clients. The accreditations reflect Concept’s ongoing strategy to implement GXP compliance across multiple sites, and to grow as a company.”
![Concept Life Sciences](https://www.cphi-online.com/gfx17/supplier.gif)
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance